|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, caspase-8 rs3834129 genotypes may not serve as predictors for CRC risk or prognosis.
|
31177115 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Archival paraffin-embedded CRC tissue samples were used to construct tissue microarray (TMA), expressions of Caspase-8 and Caspase-3 that were stained by immunohistochemistry.
|
29355114 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Contrarily, the presence of the -652 6N Del or the CASP8 302His variant was reported to be an unfavorable prognostic factor in colorectal cancer or neuroblastoma.
|
27507139 |
2016 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We observed that the CASP8 -652 6N ins/del polymorphism was significantly correlated with CRC risk when all studies were pooled into the meta-analysis (ins/del vs. ins/ins: OR = 0.890, 95%CI 0.821-0.964, P = 0.004; del/del + ins/del vs. ins/ins: OR = 0.899, 95%CI 0.833-0.970, P = 0.006).
|
24498403 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between CASP8 -652 6N del polymorphism (rs3834129) and colorectal cancer risk: results from a multi-centric study.
|
24465592 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The cleavage of Bid activated by caspase-8 might serve as a crosstalk mediator between these two pathways in CRC.
|
24957706 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no association of the CASP8 genetic variants with CRC in our case-control study.
|
23844036 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CASP8 -652 6N ins/del polymorphism may be an independent survival predictor for CRC.
|
23715747 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, silencing of SART1 led to a downregulation of the caspase-8 inhibitor, c-FLIP, which we have previously shown is a key determinant of drug resistance in colorectal cancer.
|
22027693 |
2012 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, there is an association between the CASP8 -652 6N del polymorphism and reduced cancer risk, especially among Asians, Caucasians and those with colorectal cancer.
|
22513478 |
2012 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No statistical significant association was observed between CASP8 -652 6N ins/del polymorphism frequencies and CRC susceptibility.
|
21538054 |
2011 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Caspase-8 was cleaved during exposure to suspension culture in four CRC lines, and cell death was inhibited by caspase-3 and caspase-8 inhibitors but not by a caspase-9 inhibitor.
|
18245494 |
2008 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is thus very unlikely that variation in CASP8 defined by -652 6N ins/del or D302H influences the risk of CRC in European populations.
|
18362937 |
2008 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is a tumor marker that is associated with metastasis, poor response to chemotherapy of colorectal cancer (CRC), and anoikis, a form of apoptosis caused by cell detachment from matrix that is dependent on TRAIL-R2 (DR5) and caspase-8 activation in CRC.
|
17510406 |
2007 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.
|
17450141 |
2007 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Of note, one colorectal carcinoma with the CASP6 mutation harbored CASP3 and CASP8 gene mutations as well.
|
16948818 |
2006 |
|
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to explore the possibility that mutation of the caspase-8 gene might be involved in the development of colorectal cancer.
|
12949717 |
2003 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the combination effect of 5-fluorouracil (5-FU), a first-choice drug for the treatment of colorectal cancer and adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells.
|
12692863 |
2003 |